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Summary Treatment of dyslipidemia is important for the primary and secondary
prevention of cardiovascular events. Although statins induce the intensive lower-
ing of low-density lipoprotein (LDL) cholesterol levels, two-thirds of cardiovascular
events are not prevented. Ezetimibe has been shown to be a selective inhibitor of
the Niemann-Pick C1-like 1 (NPC1L1) transporter of cholesterol across the intesti-
nal wall. Ezetimibe-based therapy may hold the promise of more intensive lowering
of LDL cholesterol. This review will address the beneﬁcial effects of ezetimibe in
patients with dyslipidemia.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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zetimibe (1-(4-ﬂuorophenyl)-(3R)-[3-(4-ﬂuoro-
henyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxypro-
yl)-2-azetidinone) is a potent inhibitor of choles-
erol and phytosterol uptake [1]. Since low
holesterol absorption has been associated with
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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Figure 1 Unadjusted Kaplan—Meier curve for total
Figure 3 Changes in serum lipid proﬁle in placebo
(n = 70, black bars), ezetimibe therapy (n = 61, white
bars), simvastatin therapy (n = 263, gray bars), and eze-
timibe + simvastatin therapy (n = 274, dotted bars) in
p
d
t
d
w
p
E
E
c
[
2mortality in the lowest quartile of serum cholestanol-
to-cholesterol ratio (n = 94) vs. other quartiles combined
(n = 284).
a lower rate of total mortality [2] (Fig. 1), phar-
macological intervention through the inhibition of
intestinal cholesterol absorption may be a useful
strategy for treating patients with dyslipidemia
and/or cardiovascular disease. Niemann-Pick C1-
like 1 (NPC1L1) has recently been identiﬁed, and
has been shown to have features of a plasma mem-
brane transporter, including a secretion signal,
13 predicted transmembrane domains, extensive
N-linked glycosylation sites and a sterol-sensing
domain [3] (Fig. 2). It is highly expressed on the
surface of absorptive jejunal enterocytes. NPC1L1
has been shown to be a direct target of ezetimibe,
and an ezetimibe-sensitive pathway plays a role in
intestinal cholesterol absorption [4]. Despite the
availability of statins, many patients do not achieve
lipid targets. Combination therapy with statins and
ezetimibe that act via a complementary pathway
may allow additional patients to achieve their
recommended cholesterol goals. These ﬁndings
represent an exciting new area in the treatment of
dyslipidemia. Ezetimibe-based therapy may hold
the promise of more intensive lowering of low-
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Figure 2 Secondary stratients with primary hypercholesterolemia. LDL, low-
ensity lipoprotein; HDL, high-density lipoprotein; TG,
riglyceride. *p < 0.05 vs. simvastatin therapy.
ensity lipoprotein (LDL) cholesterol. This review
ill address the beneﬁcial effects of ezetimibe in
atients with dyslipidemia.
zetimibe monotherapy
zetimibe can effectively lower plasma LDL
holesterol to decrease cholesterol absorption
5]. Ezetimibe at 10mg/day induced an about
0% reduction in LDL cholesterol [6] (Fig. 3). In
ddition, ezetimibe decreased triglyceride (TG) by
bout 8% and increased high-density lipoprotein
HDL) cholesterol by about 5%. In patients with
rimary dyslipidemias, ezetimibe (10mg/day)
ucture of NPC1L1.
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teneﬁcial effects of ezetimibe-based therapy
herapy for 16 weeks reduced total, LDL and non-
DL cholesterol values as well as apolipoprotein
concentrations [7]. Patients with TG values
150mg/dL had signiﬁcantly greater reductions in
he concentrations of small, dense LDL particles
ompared to those with normal TG levels (49%
s. 19%, respectively; p < 0.05). With respect
o individual LDL subfractions, cholesterol was
igniﬁcantly reduced by ezetimibe in cholesterol
n nearly all LDL subfractions [8]. These results
ndicate that ezetimibe signiﬁcantly reduces LDL
holesterol by inhibiting the reabsorption of biliary
holesterol.
zetimibe/statin combination therapy
he combination of ezetimibe and statin therapy
ay synergistically decrease cholesterol absorp-
ion and synthesis, since the effective inhibition
f cholesterol synthesis and the subsequent reduc-
ion in serum cholesterol levels by statins lead
o increases in serum plant-sterol levels, proba-
ly as a result of reduced biliary secretion and the
nhanced absorption of these sterols [9].
In 769 patients with hypercholesterolemia,
ngoing statin therapy plus ezetimibe led to sig-
iﬁcant changes in LDL cholesterol (of −25.1%)
HDL cholesterol +2.7%; TG −14.0%) compared
o the results with placebo (LDL cholesterol
3.7%, HDL cholesterol +1.0%, and TG −2.9%)
10]. Among patients who were not at their LDL
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igure 4 Changes in serum LDL cholesterol levels in patients w
zetimibe Trial). After 6 months of ezetimibe monotherapy (s
otted line) was started in poor-responders (n = 26) after 6 m
inued ezetimibe monotherapy (gray line).3
holesterol target, 71.5% of those who received
tatin plus ezetimibe vs. 18.9% of those who
eceived statin plus placebo reached their target
evels at the end-point. In multicenter, random-
zed, double-blind, placebo-controlled studies, an
zetimibe + simvastatin group showed signiﬁcantly
mproved LDL cholesterol, HDL cholesterol, and
G compared to a simvastatin-alone group. Eze-
imibe plus simvastatin provided an incremental
3.8% LDL cholesterol decrease, 2.4% HDL choles-
erol increase, and 7.5% TG decrease compared to
imvastatin alone (Fig. 3) [6]. We also performed
he Fluvastatin Add-On to Ezetimibe Trial (FAET) in
atients with hypercholesterolemia (Fig. 4). After
months of ezetimibe monotherapy (10mg/day),
lasma LDL cholesterol decreased by 40mg/dl
mean: 175—135mg/dl at 6 months). Ezetimibe
lus low-dose of ﬂuvastatin (20mg/day) combi-
ation therapy was started in poor-responders
LDL cholesterol: 158± 4mg/dl after 6 months
zetimibe monotherapy), then the LDL choles-
erol levels reduced to 130± 4mg/dl (−28mg/dl),
hile LDL cholesterol in ezetimibe monotherapy
roup (responders) was 128± 4mg/dl. No adverse
ffect was observed. Although coadministration of
zetimibe plus low-dose of ﬂuvastatin was more
ffective in reducing plasma concentrations of LDL-
than ezetimibe alone, we need to analyze the
atient’s characteristics of poor-responder to eze-
imibe.
Combination therapy with 10mg/day ezetim-
be and 10mg/day atorvastatin for 8 weeks
ith hypercholesterolemia (n = 59) (Fluvastatin Add-On to
olid line), combination therapy (ezetimibe +ﬂuvastatin,
onths ezetimibe monotherapy. Responders (n = 33) con-
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resulted in signiﬁcantly decreased total serum
cholesterol and TG compared to 40mg/day ator-
vastatin alone [11]. Ezetimibe/atorvastatin therapy
signiﬁcantly improved LDL cholesterol, HDL choles-
terol, TG and high-sensitivity C-reactive protein
(hs-CRP) compared to atorvastatin alone [12].
The addition of ezetimibe to on-going simvas-
tatin treatment also resulted in a signiﬁcantly
greater percent reduction in LDL cholesterol from
baseline (25.2%) compared to the results with
placebo (0.9%). In a double-blind, multicenter, 6-
week, parallel-group study, hypercholesterolemic
patients were randomized to receive ezetim-
ibe/simvastatin or rosuvastatin. At all doses
and across doses, ezetimibe/simvastatin reduced
LDL cholesterol signiﬁcantly more than rosuvas-
tatin [13]. Ezetimibe/simvastatin also produced
signiﬁcantly greater reductions in total choles-
terol, non-HDL cholesterol and apolipoprotein B.
Intensive lipid-lowering therapy with rosuvastatin
40mg/day provided a greater LDL cholesterol-
lowering effect than atorvastatin 80mg/day, which
enabled more patients to achieve their LDL choles-
terol goals [13]. The EXPLORER study was designed
to investigate the efﬁcacy and safety of rosu-
vastatin 40mg/day alone or in combination with
ezetimibe 10mg/day in patients with a high risk of
coronary heart disease [14]. Interestingly, the com-
bination of rosuvastatin/ezetimibe reduced LDL
cholesterol signiﬁcantly more than rosuvastatin
alone. Other components of the lipid/lipoprotein
proﬁle were also signiﬁcantly improved with rosu-
vastatin/ezetimibe. This combination therapy may
have the strongest lipid-lowering effect.
The combination of ezetimibe/statin therapy
reduced LDL cholesterol by 57% in familial hyperc-
holesterolemia (FH) patients, regardless of the type
of LDL receptor mutation. In clinical trials, eze-
timibe/simvastatin produced greater reductions in
LDL cholesterol than did monotherapy [15]. A possi-
ble molecular mechanism of the enhanced efﬁcacy
of ezetimibe plus simvastatin is decreased very
(V) LDL and LDL apoB-100 concentrations through
reduced VLDL production and the upregulation of
LDL receptor-mediated LDL clearance. The addi-
tional decrease in plasma LDL cholesterol induced
by ezetimibe showed wide inter-individual variabil-
ity and was negatively correlated with the percent
decrease in LDL cholesterol due to statin alone
[16]. The reduction in LDL cholesterol in FH het-
erozygotes following combined therapy may affect
the complex interplay between hepatic synthe-
sis and the intestinal absorption of cholesterol.
The usefulness of ezetimibe in enhancing the efﬁ-
cacy of apheresis therapy was evaluated in six
Japanese patients with homozygous FH undergoing
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DL-apheresis in combination with atorvastatin or
imvastatin [17]. Thus ezetimibe also appears to be
seful in combination with statins for FH patients.
Since diabetes mellitus (DM) patients have been
hown to have more NPC1L1 mRNA than control
ubjects [18], ezetimibe may be useful for the
reatment of patients with DM in whom cholesterol
bsorption may be upregulated. In patients with
ype 2 DM, combination therapy is usually required
o optimize glucose metabolism as well as to help
atients achieve aggressive targets for LDL choles-
erol and other lipid parameters associated with
ardiovascular risk. Ezetimibe/simvastatin therapy
as effective and well tolerated under actual prac-
ice conditions in high-risk patients with coronary
eart disease and/or DM [19]. In a randomized,
ouble-blind, multicenter study in type 2 DM
atients, LDL cholesterol was reduced signiﬁcantly
ore by adding ezetimibe 10mg/day to simvas-
atin 20mg/day than by doubling the dose of
imvastatin to 40mg/day [20]. In addition, ezetim-
be + simvastatin therapy also produced signiﬁcant
ncremental reductions in non-HDL cholesterol,
ery LDL cholesterol and apolipoprotein B relative
o simvastatin 40mg/day.
zetimibe or ezetimibe/statin in
ombination with ﬁbrate therapy
lthough fenoﬁbrate did not signiﬁcantly reduce
he risk of the primary outcome of coronary events,
t did reduce total cardiovascular events, mainly
ue to fewer non-fatal myocardial infarctions and
evascularizations in patients with type 2 DM [21].
ixed hyperlipidemia is an important risk factor
or the development of cardiovascular disease.
enoﬁbrate and ezetimibe offer complementary
eneﬁts to the lipid proﬁle in patients with
ixed hyperlipidemia. Patients in the fenoﬁbrate
lus ezetimibe and fenoﬁbrate groups continued
n their respective base study treatment, and
atients in the ezetimibe and placebo groups
ere switched to fenoﬁbrate plus ezetimibe and
enoﬁbrate, respectively [22]. Fenoﬁbrate plus
zetimibe produced signiﬁcantly greater reduc-
ions in LDL cholesterol than fenoﬁbrate alone.
here were also signiﬁcantly greater improve-
ents in TG, HDL cholesterol, total cholesterol,
on-HDL cholesterol, and apolipoprotein B with
enoﬁbrate plus ezetimibe than with fenoﬁbrate
lone. In a multicenter, randomized, double-
lind, placebo-controlled, parallel arm trial, the
DL cholesterol level was signiﬁcantly reduced
ith ezetimibe/simvastatin + fenoﬁbrate com-
ared fenoﬁbrate or placebo, but not compared
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Reneﬁcial effects of ezetimibe-based therapy
o ezetimibe/simvastatin [23]. HDL cholesterol
nd apolipoprotein A-I levels were signiﬁcantly
ncreased with ezetimibe/simvastatin + fenoﬁbrate
reatment compared to with ezetimibe/simvastatin
r placebo. TG, non-HDL cholesterol, and
polipoprotein B levels were signiﬁcantly reduced
ith ezetimibe/simvastatin + fenoﬁbrate vs. all
ther treatments. Thus, the coadministration
f ezetimibe/statin plus fenoﬁbrate effectively
mproved the overall atherogenic lipid proﬁle of
atients with hyperlipidemia.
enetic studies on ezetimibe therapy
he NPC1L1 gene may have naturally occur-
ing coding mutations. These mutations might
ffect the response to ezetimibe among individuals
ho carry such mutants. In fact, three com-
on single-nucleotide polymorphisms have been
ound in NPC1L1 (1735C >G [L272L], 25342A >C and
7677T >C [V1296]). Different NPC1L1 protein vari-
nts, such as Val55 to Leu55 and Ile1233 to Asp1233
ave been found in a non-responder to ezetim-
be [24]. In addition, 101 patients with primary
ypercholesterolemia had a signiﬁcantly greater
eduction in plasma LDL cholesterol with ezetimibe
han subjects with at least one copy of the haplo-
ype. A detailed characterization of DNA variations
n NPC1L1, the target of ezetimibe, demonstrated
hat common variants in this gene are signiﬁcantly
ssociated with the LDL cholesterol reduction in
esponse to treatment with ezetimibe combined
ith a statin, but not with baseline LDL cholesterol
25]. Moreover, genetic variation in NPC1L1 con-
ributes to the variability in cholesterol absorption
nd plasma levels of LDL cholesterol [26]. Rare vari-
nts identiﬁed in low-absorbers were found in 6% of
832 African-Americans and were associated with
ower plasma levels of LDL cholesterol. Although
one of these common or rare variants have been
onﬁrmed, evidence has indicated an association
etween LDL cholesterol and NPC1L1 gene produc-
ion as a target for ezetimibe.
afety of ezetimibe
n 2382 patients with primary hypercholes-
erolemia, the coadministration of ezetimibe plus
tatin was well-tolerated [27]. In addition, in
randomized, double-blind, placebo-controlled
rial, the safety and tolerability proﬁles for the
zetimibe/simvastatin and ezetimibe monotherapy
roups were similar [28]. Ezetimibe plus statin
herapy was well-tolerated and had a favorable5
afety proﬁle in both male and female subgroups
29]. The coadministration of ezetimibe and statin
as equally safe across speciﬁc age groups: age
65 vs. ≥65 years; age <75 vs. more than 75
ears [30]. Simvastatin at doses up to 40mg is a
ell-tolerated and effective therapy for children
ith heterozygous familial hypercholesterolemia
31]. In addition, the combination of fenoﬁbrate
lus ezetimibe was well tolerated during the
xtension study, with similar rates of ALT/AST
levations between fenoﬁbrate plus ezetimibe and
enoﬁbrate alone [22]. Overall, ezetimibe shows a
avorable safety proﬁle across all patients.
onclusions
zetimibe is one of the most important medica-
ions for inhibiting cholesterol absorption. It has
een shown to signiﬁcantly reduce LDL choles-
erol and improve other lipid parameters as either
onotherapy or in combination therapy with other
ipid-lowering medications, such as statins and
brates. Such combination therapy is a more effec-
ive therapeutic option for the intensive lowering of
DL cholesterol. In addition, this therapy has been
hown to have a favorable safety proﬁle across all
atients. Large randomized trials will be needed to
valuate the effectiveness of ezetimibe/statin or
zetimibe/ﬁbrate therapy on clinical endpoints for
he risk of coronary artery disease.
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